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Summary
Background: Nowadays, early detection and treatment can often keep chronic kidney
disease patients from getting worse and prevent the occurrence of cardiovascu-
lar disease. Cystatin C (Cys-C) is a new marker for renal dysfunction. This study
investigated whether Cys-C played an important role for screening coronary artery
disease.
Methods: The consecutive 88 outpatients (51 males and 37 females), who were
suspected of having effort angina pectoris or asymptomatic ischemic heart disease,
were enrolled. Serum Cys-C, which was obtained within 3 months before coronary
angiography, was assessed with the presence or absence of coronary arteriosclerosis,
the number of culprit arteries, and blood biochemical parameters.
Results: Mean serum Cys-C was 0.82± 0.29mg/l. Signiﬁcant differences in the esti-
mated creatinine clearance (p = 0.036), hemoglobin A1c (p = 0.01), left ventricular
ejection fraction (p = 0.01), creatinine (p = 0.007), Cys-C (p = 0.006), and high-density
lipoprotein (HDL) cholesterol (p = 0.001) were observed between the patients with or
without coronary arteriosclerosis. Serum Cys-C was signiﬁcantly greater in the multi-
vessel disease (MVD) group than the 0 vessel disease (0VD) group (p < 0.001). HDL
antly lower in the MVD group than the 0VD and single-vesselcholesterol was signiﬁc
disease groups (p = 0.002 and p = 0.005, respectively).
∗ Corresponding author. Tel.: +81 44 977 8111; fax: +81 44 976 7093.
E-mail address: sekimal@marianna-u.ac.jp (H. Sekizuka).
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Conclusion: The results of this study suggest Cys-C might be one of the risk factors
for coronary arteriosclerosis in the patients with suspected ischemic heart disease
without any history of coronary artery disease. Cys-C was a useful marker to detect
coronary artery disease and the level of Cys-C could reﬂect the severity of coronary
arteriosclerosis.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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Background
In 2002, the Kidney Disease Outcomes Quality Initia-
tive (K/DOQI) of the US National Kidney Foundation
(NKF) published clinical practice guidelines for
chronic kidney disease (CKD) [1]. Nowadays, CKD
has gained broad attention because many patients
suffer from this disease. The National Health and
Nutrition Examination Survey (NHANES), which was
conducted between 1999 and 2004 in the USA, has
reported that approximately 13% of adults aged 20
years or older have CKD [2]. In Japan, it is reported
that the number of patients with CKD Stage 3 to
Stage 5 is approximately 19 million according to the
estimation of glomerular ﬁltration rate by the mod-
iﬁcation of Diet in Renal Disease (MDRD) equation
[3] modiﬁed for Japanese patients with CKD [4].
Individuals who are in the early phase of CKD
have no symptoms. When CKD exacerbates, it may
eventually lead to kidney failure. Moreover, CKD
increases the risk of having cardiovascular disease
(CVD). Sarnak et al. [5] concluded that CKD is an
independent predictor of the composite outcome of
all-cause mortality and CVD in the general popula-
tion; early detection and treatment can often keep
CKD from getting worse and prevent the onset of
CVD.
Cystatin C (Cys-C) is a non-glycosylated protein
with low molecular mass (13 kDa) in the cystatin
superfamily. Cys-C belongs to the cysteine pro-
teinase inhibitors and is produced at a constant
rate in all nucleated cells. It is removed from
blood plasma by glomerular ﬁltration in the kid-
neys and reabsorbed by the proximal tubule and
degraded. There is a linear relationship between
the reciprocal Cys-C concentration in plasma and
the glomerular ﬁltration rate (GFR); Cys-C is con-
sidered as a reliable marker for GFR [6,7].
To date, it has been reported that serum Cys-C
independently predicts the occurrence of cardio-
vascular events and death from CVD [8]. Another
study has demonstrated that Cys-C is a novel pre-
dictor of outcome in patients with acute coronary
syndrome [9]; however, no study has clariﬁed the
relationship between Cys-C and risk factors for
coronary arteriosclerosis.
S
S
i
cIn the present study, we hypothesized that Cys-C
ight be useful to detect early renal insufﬁciency
n a variety of renal diseases for which early
etection and treatment was critical. Since Cys-
is associated with renal insufﬁciency and CVD,
e conducted this study on patients without any
istory of coronary artery disease to investigate
ur hypothesis, whether Cys-C could be prognostic
or cardiovascular events, especially for coronary
rtery disease.
ubjects and methods
ubjects
his study was conducted on 88 outpatients (51
ales and 37 females) who were suspected of
aving effort angina pectoris or asymptomatic
schemic heart disease from the results of tread-
ill exercise test, stress myocardial scintigraphy,
nd Holter recording, and those who visited St Mar-
anna Yokohama-city Seibu Hospital and underwent
oronary angiography between November 2005 and
ecember 2006. The patients with acute myocar-
ial infarction, unstable angina pectoris, organic
eart diseases, renal diseases (except those receiv-
ng dialysis), respiratory diseases, those aged <15
ears, or who did not undergo coronary angiography
ere excluded from this study.
All study subjects were asked to ﬁll in the ques-
ionnaire concerning any history of hypertension,
iabetes mellitus, disorders of lipid metabolism,
nd smoking. We also investigated prescribed med-
cations and dosing regimen, including antiplatelet
gent, coronary vasodilator, calcium antagonist,
-blocker, angiotensin-converting enzyme inhibitor
ACE-I), angiotensin II receptor blocker (ARB),
nsulin, p.o. antidiabetics, and medications forerum Cys-C measurement
erum Cys-C was measured at our outpatient facil-
ty or during admission within 3 months before
oronary angiography according to the latex con-
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Tystatin C and ischemic heart disease
ensation method (Mitsubishi Chemical Medience
o. Ltd., Tokyo, Japan). The measurement was per-
ormed immediately after blood collection using
nti-human Cys-C polyclonal antibodies developed
n rabbit and turbidity analysis which was an optical
easurement with scattered light. The stabilizing
gent was added to the collected blood sample
3.0l) which was kept at 37 ◦C for 5min; anti-
uman Cys-C polyclonal antibodies were added.
fterwards, the blood sample kept at 37 ◦C was
easured at 1 and 5min later, respectively, using
bsorbance at dominant wavelength of 570 nm
nd subwavelength of 800 nm. In all study sub-
ects, interfering substances, such as the serum
emoglobin and bilirubin concentration and turbid-
ty, had no inﬂuence on measuring serum Cys-C.
lood parameters
emoglobin (Hb), fasting plasma glucose (FPG),
bA1c, total cholesterol, high-density lipoprotein
HDL) cholesterol, low-density lipoprotein (LDL)
holesterol, triglyceride, and creatinine (Cr) were
easured on the previous day or on the day of
oronary angiography in the fasting state. Creati-
ine clearance (CCr) was estimated according to
he method described by Horio et al. [10].
valuation of coronary arteriosclerosis
oronary arteriosclerosis was evaluated after
oronary angiography according to the following
uideline described by the American Heart Associa-
ion [11]. (1) The coronary arteries were divided
nto 15 segments as follows: the right coronary
rtery, segments 1—4; the left main trunk, segment
; the left anterior descending artery, segments
—10; and the left circumﬂex artery, segments
1—15. (2) The severity of stenosis was evaluated
n the 6 grades as follows: 25% stenosis, 0—25%;
0% stenosis, 26—50%; 75% stenosis, 51—75%; 90%
tenosis, 76—90%; 99% stenosis, 91—99%; and com-
lete occlusion, 100%. Coronary angiograms were
ssessed by at least two cardiologists. Signiﬁcant
tenosis was deﬁned as 50% and more in the left
ain trunk or 75% and more in the other coro-
ary arteries. All subjects were classiﬁed into
he following groups: the patients without signif-
cant stenosis, the 0 vessel disease (0VD) group;
hose with signiﬁcant stenosis in the one coronary
rtery, the single-vessel disease (SVD) group; those
ith signiﬁcant stenosis in two and more coronary
rteries or stenosis in the left main trunk, themulti-
essel disease (MVD) group; and those classiﬁed into
he 1VD and MVD groups, the ischemic heart disease
IHD) group.
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thics
his study was performed in accordance with the
thical principles set forth in the Declaration of
elsinki. The study protocol was approved by the
t Marianna University School of Medicine Institu-
ional Committee of Human Research (No. 613).
he nature and purpose of the study and the risks
nvolved were explained to all subjects before their
nrollment, and written informed consent to par-
icipation in the study was obtained.
tatistical analysis
he data are expressed as mean± SD. Differences
etween two groups were analyzed using Fisher
xact test; differences between each group were
nalyzed using analysis of variance. In addition, the
onferroni correction was used for multiple test-
ng; the signiﬁcant p level was set at p < 0.016. To
etermine the important prognostic factors, uni-
ariate and multivariate analyses were performed,
espectively. All analysis was performed using JMP
oftware for Windows (version 7.0; SAS Institute,
arey, NC, USA). Statistical signiﬁcance was estab-
ished at p < 0.05.
esults
ubjects’ backgrounds
n total, 88 patients (51 males and 37 females) com-
leted necessary items. Mean age was 67.3± 9.1
ears (Table 1), mean Cys-C was 0.82± 0.29mg/l.
e assessed the factors that might affect Cys-C.
ince most of the patients revealed relatively good
enal function, they were divided into Cys-C 0.89
r 0.90mg/l based on the results demonstrated
y Shlipak et al. [8]. The patients with Cys-
 90 were signiﬁcantly older (p = 0.005), greater
umber of smokers (p = 0.029), and -blocker
p < 0.001) and ACE-I/ARB administration (p = 0.005;
able 1). Moreover, signiﬁcant differences in the
DL cholesterol (p = 0.014), Cr (p < 0.001), esti-
ated CCr (eCCr; p < 0.001), and Cys-C (p < 0.001)
ere observed between the patients with Cys-C
0.89 and 0.90mg/l (Table 2).
he relationship between Cys-C and eCCrhe serum Cys-C in the patients with
CCr < 50ml/min (1.54± 0.65mg/l) was signif-
cantly greater than that of those with eCCr
1—70ml/min (0.89± 0.19mg/l, p < 0.001), eCCr
1—90ml/min (0.74± 0.12mg/l, p < 0.001) and
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Table 1 Patient backgrounds.
Cystatin C (mg/l) All subjects 0.89 0.90 p-Value
Number of patients 88 68 20
Male sex no. (%) 51(58) 37(54) 14(70) n.s.
Age (year) 67.3± 9.1 65.9± 8.3 72.3± 9.9 0.005
Height (cm) 158.9± 8.5 158.4± 8.3 160.0± 9.5 n.s.
Weight (kg) 59.6± 10.0 59.3± 10.1 60.6± 9.7 n.s.
BMI (kg/m2) 23.5± 2.9 23.5± 2.9 23.6± 2.7 n.s.
Hypertension no. (%) 65(65) 48(60) 17(85) n.s.
Diabetes no. (%) 27(27) 22(28) 5(25) n.s.
Hyperlipidemia no. (%) 46(46) 41(51) 5(25) n.s.
Smoking habit no. (%) 11(11) 5(6) 6(30) 0.029
EAP no. (%) 66(66) 54(68) 12(60) n.s.
SMI no. (%) 22(22) 15(19) 7(35) n.s.
Antiplatelet agent no. (%) 61(69) 46(67) 15(75) n.s.
Nitroglycerin no. (%) 32(36) 26(38) 6(30) n.s.
Calcium antagonist no. (%) 29(33) 24(35) 5(25) n.s.
Beta blocker no. (%) 23(26) 12(18) 11(55) <0.001
ACE-I/ARB no. (%) 38(38) 25(31) 13(65) 0.005
Insulin no. (%) 15(17) 12(18) 3(15) n.s.
Statin no. (%) 19(22) 14(21) 5(25) n.s.
ocar
ction
s
C
e
a
c
C
C
o
TLVEF (%) 63.7± 12.7
BMI, body mass index; EAP, effort angina pectoris; SMI, silent my
ARB, angiotensin II receptor blocker; LVEF, left ventricular eje
eCCr >91ml/min (0.69± 0.09mg/l, p < 0.001).
The patients with eCCr 51—70ml/min had signiﬁ-
cantly greater serum Cys-C than those with eCCr
71—90ml/min (p = 0.013) and eCCr > 91ml/min
(p = 0.002).
Blood parameters evaluated in the patients
with or without coronary arteriosclerosis
Each biochemical blood parameter was assessed
between the IHD and 0VD groups (Table 3).
There were signiﬁcant differences in gender
(p = 0.037), the patients treated with or without
antiplatelet agents (p = 0.030), coronary vasodila-
tors (p = 0.042), -blockers (p = 0.015), and/or
c
a
s
a
Table 2 Baseline characteristics.
Cystatin C (mg/l) All subjects 
Hemoglobin (g/dl) 13.3 ± 1.4
FPG (mg/dl) 103.2 ± 19.0
Hemoglobin A1c (%) 5.4 ± 0.6
Total cholesterol (mg/dl) 182.6 ± 34.0 1
HDL cholesterol (mg/dl) 49.1 ± 14.7
LDL cholesterol (mg/dl) 108.2 ± 26.0 1
TG (mg/dl) 132.7 ± 64.5 1
Creatinine (mg/dl) 0.86 ± 0.32
eCCr (ml/min) 78.2 ± 19.3
Cystatin C (mg/l) 0.82 ± 0.29
FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, lo
tinine clearance.65.4± 10.6 57.6± 16.9 0.014
dial ischemia; ACE-I, angiotensin-converting enzyme inhibitor;
fraction.
tatins (p = 0.015), HDL cholesterol (p = 0.001),
ys-C (p = 0.006), Cr (p = 0.007), left ventricular
jection fraction (LVEF, p = 0.01), HbA1c (p = 0.010),
nd eCCr (p = 0.036) between the two groups; espe-
ially, the differences in the HDL cholesterol and
ys-C were remarkable.
oronary artery stenosis evaluation based
n each blood parameter
he logistic regression analysis was performed using
oronary artery stenosis as a dependent valu-
ble (Table 4). We evaluated the parameters that
howed signiﬁcant differences between the 0VD
nd IHD groups in Table 3 and their inﬂuence on
0.89 0.90 p-Value
13.4 ± 1.4 12.9 ± 1.5 n.s.
95.9 ± 14.4 105.3 ± 19.8 n.s.
5.4 ± 0.6 5.3 ± 0.5 n.s.
85.4 ± 35.6 173.2 ± 26.3 n.s.
51.2 ± 15.4 42.1 ± 8.7 0.014
09.2 ± 26.5 104.9 ± 24.6 n.s.
31.0 ± 68.8 138.6 ± 48.4 n.s.
0.77 ± 0.15 1.19 ± 0.47 <0.001
84.1 ± 16.2 58.3 ± 15.2 <0.001
0.72 ± 0.09 1.19 ± 0.42 <0.001
w-density lipoprotein; TG, triglyceride; eCCr estimated crea-
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Table 3 Blood parameters evaluated in the patients with or without coronary arteriosclerosis.
0VD IHD p-Value
Number of patients 34 54
Male sex no. (%) 15(44) 36(67) 0.037
Age (year) 66.4± 7.8 67.9± 9.8 n.s.
Height (cm) 158.1± 9.0 159.2± 8.3 n.s.
Weight (kg) 58.0± 11.8 60.6± 8.6 n.s.
BMI (kg/m2) 23.0± 3.1 23.9± 2.7 n.s.
Hypertension no. (%) 26(41) 37(59) n.s.
Diabetes no. (%) 4(16) 21(84) n.s.
Hyperlipidemia no. (%) 14(37) 24(63) n.s.
Smoking habit no. (%) 4(31) 9(69) n.s.
EAP no. (%) 15(44) 21(66) n.s.
SMI no. (%) 0(0) 15(68) /
Antiplatelet agent no. (%) 19(31) 42(69) 0.03
Nitroglycerin no. (%) 8(25) 24(75) 0.042
Calcium antagonist no. (%) 11(38) 18(62) n.s.
Beta blocker no. (%) 4(17) 19(83) 0.015
ACE-I/ARB no. (%) 16(42) 22(58) n.s.
Insulin no. (%) 3(20) 12(80) n.s.
Statin no. (%) 6(21) 23(79) 0.015
LVEF (%) 67.7± 9.8 61.1± 13.6 0.01
Hemoglobin (g/dl) 13.3± 1.4 13.3± 1.4 n.s.
FPG (mg/dl) 103.5± 17.8 102.9± 19. 9 n.s.
Hemoglobin A 1c (%) 5.2± 0.5 5.5± 0.6 0.01
Total cholesterol (mg/dl) 191.2± 41.7 177.1± 27. 1 n.s.
HDL cholesterol (mg/dl) 55.4± 19.0 45.2± 9.3 0.001
LDL cholesterol (mg/dl) 113.0± 30.9 105.1± 2 2.2 n.s.
TG (mg/dl) 124.9± 73.6 137. 6± 58.3 n.s.
Creatinine (mg/dl) 0.75± 0.16 0.93± 0.37 0.007
Estimated CCr (ml/min) 83.6± 18.6 74.8± 19.0 0.036
Cystatin C (mg/l) 0.72± 0.11 0.89± 0.35 0.006
BMI, body mass index; EAP, effort angina pectoris; SMI, silent myocardial ischemia; ACE-I, angiotensin-converting enzyme inhibitor;
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sARB, angiotensin II receptor blocker; LVEF, left ventricular e
lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; CC
oronary artery stenosis. The results of univariate
nalysis showed a signiﬁcant relationship between
he occurrence of coronary artery stenosis and
ender, the patients who were treated with or
ithout antiplatelet agents, coronary vasodilators
nd/or statins, LVEF, HbA1c, HDL cholesterol, Cr,
CCr or Cys-C; especially, the HDL cholesterol and
ys-C remarkably correlated. Multivariate analysis
sing Pearson and Deviance residuals demonstrated
hat HDL cholesterol was the only independent risk
actor. Meanwhile, the odds ratio of Cys-C was
emarkably high (20.92).
he relationship between the number of
ulprit arteries and each blood parametern the present study, all patients were classiﬁed
ccording to the number of culprit arteries; 34
atients in the 0VD group, 25 in the SVD group and
9 in the MVD group (Fig. 1). The Cys-C was sig-
a
t
n
s
pon fraction; FPG, fasting plasma glucose; HDL, high-density
atinine clearance.
iﬁcantly greater in the MVD group than the 0VD
roup (p < 0.001). The HDL cholesterol was signif-
cantly lower in the MVD group than the 0VD and
VD groups (p = 0.002 and p = 0.005, respectively).
n addition, signiﬁcantly lower LVEF and greater Cr
ere observed in the MVD group compared with the
VD group (p = 0.002 and p = 0.006, respectively).
o signiﬁcant difference in HbA1c was observed
etween the number of culprit arteries and Cys-C.
iscussion
n the present study, we evaluated the relation-
hip between Cys-C and the occurrence of coronary
rtery sclerosis. The results of this study suggested
hat Cys-C was a useful marker for detecting coro-
ary artery disease. Moreover, Cys-C reﬂected the
everity of signiﬁcant coronary artery stenosis in
atients who were suspected of having IHD.
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Table 4 Logistic regression analysis.
Univariate analysis Odds ratio 95% CI p-Value Adaption
Variable Pearson Deviance Likelihood ratio
Sex (male = 1) 2.53 1.048—6.122 0.039 / / 0.037
Antiplatelet agent (yes = 1) 2.53 1.087—7.023 0.327 / / 0.313
Nitroglycerin (yes = 1) 2.53 0.998—6.771 0.050 / / 0.436
Beta blocker (yes = 1) 2.53 1.247—13.296 0.020 / / 0.011
Statin (yes = 1) 2.53 1.231—9.734 0.185 / / 0.013
LVEF (%) 2.53 0.909—0.993 0.022 0.365 0.121 0.011
Hemoglobin A1c (%) 2.53 0.324—5.018 0.008 0.244 0.137 0.002
HDL cholesterol (mg/dl) 2.53 3.818—242.665 0.001 0.651 0.250 <0.001
Cr (mg/dl) 44.92 1.955—195.676 0.006 0.405 0.062 <0.001
eCCr (ml/min) 0.98 1.626—87.091 0.040 0.429 0.028 0.033
Cystatin C(mg/l) 193.31 5.258—7106.433 0.004 0.402 0.100 <0.001
Multivariate analysis Odds ratio 95% CI p-Value Adaption
Variable Pearson Deviance Likelihood ratio
Sex (male = 1) 2.87 0.859—9.563 0.087 0.527 0.266 <0.001
Beta blocker (yes = 1) 1.79 0.439—7.275 0.417
LVEF (%) 0.95 0.904—1.002 0.061
HDL cholesterol (mg/dl) 0.95 0.901—0.999 0.046
Cr (mg/dl) 1.96 0.016—241.620 0.785
eCCr (ml/min) 0.99 0.953—1.031 0.672
Cystatin C (mg/l) 20.92 0.118—3693.225 0.249
CI, conﬁdence interval; LVEF, left ventricular ejection fraction; HDL, high-density lipoprotein; Cr, creatinine; eCCr, estimated
creatinine clearance.
Figure 1 The relationship between the number of culprit arteries and blood parameters. (A) The left ventricular
function (LVEF) was signiﬁcantly lower in the 0 vessel disease (0VD) than the multi-vessel disease (MVD) group. (B)
There was no difference in hemoglobin (Hb) A1c between groups. (C) The high-density lipoprotein (HDL) cholesterol
was signiﬁcantly lower in the MVD group than the 0VD and single-vessel disease (SVD) groups (p = 0.002 and p = 0.005,
respectively). (D) The creatinine (Cr) was signiﬁcantly greater in the MVD than 0VD group (p = 0.006). (E) The serum
cystatin-C (Cys-C) was signiﬁcantly greater in the MVD group than the 0VD groups (p < 0.001).
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hystatin C and ischemic heart disease
he relationship between Cys-C and eCCr
n general, estimated GFR (eGFR) is used to
etermine and classify the severity of CKD [1];
owever, renal function tends to be less accu-
ate due to underestimated eGFR in patients with
FR 60ml/min/1.73m2 [12]. Since this study did
ot include patients with obvious renal dysfunc-
ion or diseases, some of our subjects’ eGFR might
e around 60ml/min/1.73m2. Therefore, we eval-
ated Cys-C using eCCr according to the formula
nd monogram for predicting CCr described by
orio et al. [10], which took the following points
nto consideration: (1) many patients with eGFR
0ml/min/1.73m2 might be included in this study,
2) this formula was modiﬁed for Japanese patients,
nd (3) it also included the parameters of obe-
ity. In some cases, serum Cys-C could not detect
arly renal insufﬁciency; however, the results of
his study suggested that serum Cys-C might be
seful to evaluate renal function. This result was
imilar to the one demonstrated by Shimizu-Tokiwa
t al. [13].
he number of culprit coronary arteries and
ys-C
hen we assessed each blood parameter in the
resence or absence of coronary artery stenosis,
ys-C and HDL cholesterol showed signiﬁcant differ-
nces. This suggested that not only HDL cholesterol,
ut also Cys-C could be a useful marker for screen-
ng coronary arteriosclerosis. Compared with Cr
nd eCCr, which is regarded as a marker of renal
nsufﬁciency, Cys-C reﬂected more precisely the
resence or absence of coronary artery steno-
is. Unfortunately, we failed to clarify why Cys-C
ncreased; however, it might be caused by the fol-
owing reasons: decreased renal function induced
he occurrence of coronary artery stenosis or Cys-
was increased by some factors. Some studies
14,15] have reported that atherosclerotic lesions
ontain much more cathepsin S and K mRNAs and
roteins than normal arteries, which causes the
egradation of the vascular wall. It is said that
he Cys-C concentration increases in arteriosclero-
is lesions and decreases in blood ﬂow in the same
ndividual; however, it has not been fully eluci-
ated.
The results of this study were similar to pre-
ious studies [16—18]; decreased HDL cholesterol
ontributed to the occurrence of coronary artery
isease. In the patients without any history of
oronary artery disease, Cys-C itself could possi-
ly screen and specify coronary artery stenosis in
atients with suspected coronary arteriosclerosis.
t
n
n
i
c365
n this study, we hypothesized that Cys-C was a new
arker for screening coronary arteriosclerosis and
ssessed the obtained data according to the logistic
egression analysis using coronary artery stenosis
s a dependent valuable (Table 4). The result of
ultivariate analysis indicated that HDL cholesterol
as the only independent risk factor. Meanwhile,
he Cys-C odds ratio was remarkably high (20.92),
hich suggested that Cys-C might also be useful
or screening. It is noteworthy that 18 (90%) of the
0 patients with Cys-C 0.90mg/l had signiﬁcant
tenosis. The odds ratio of signiﬁcant stenosis in the
atients with Cys-C0.90mg/l vs. those with Cys-C
0.89mg/l was 1.70, which supported our hypoth-
sis that Cys-C could be recognized as a new marker
or screening coronary arteriosclerosis.
When the patients were divided into Cys-C
0.89mg/l or Cys-C 0.90mg/l, no signiﬁcant
ifferences in the history of diabetes mellitus,
ypertension, and disorders of lipid metabolism
ere observed; however, signiﬁcant differences in
bA1c and HDL cholesterol were observed between
he patients with and without coronary artery
tenosis. This result was attributed to the fact
hat diabetes mellitus and disorders of lipid abnor-
ality were independent risk factors for coronary
rteriosclerosis. Since many patients have both
iseases, the occurrence rate of coronary artery
isease increases [19—21]. It is still a matter of
ebate how renal dysfunction speciﬁcally induces
rteriosclerosis; however, traditional risk factors,
uch as diabetes mellitus and disorders of lipid
etabolism, possibly correlate and accelerate the
rogress of arteriosclerosis [5]. In the present
tudy, signiﬁcant differences in Cys-C, Cr, and eCCr
epending on the number of culprit arteries might
e due to the correlation between disorders of glu-
ose and lipid metabolism.
he severity of coronary stenosis and Cys-C
ys-C of the patients with MVD signiﬁcantly
ncreased compared with that of those with 0VD.
he level of Cys-C tended to increase as the number
f culprit arteries increased.
This result suggested that Cys-C possibly
ncreased as the severity of coronary artery dis-
ase increased. Nowadays, 64-slice multidetector
omputed tomography (MSCT) is widely used to
etect coronary artery stenosis. Since the negative
it ratio of MSCT is estimated to be 97—98% [22],
he patients avoid undergoing unnecessary coro-
ary angiography. However, sometimes MSCT can
either detect coronary artery disease nor classify
ts severity in patients with calciﬁed lesions, tachy-
ardia, or arrhythmia and those who stop breathing
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[
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during MSCT. Thus, the negative hit ratio becomes
lower; the patients have to undergo both MSCT
and coronary angiography. Recent studies have
demonstrated the usefulness of non-traditional bio-
chemical markers [23,24]; in this aspect, serum
Cys-C, which is obtained from blood samples, is
noninvasive and useful for screening IHD and esti-
mating its severity. Several studies have reported
that there is a weak but positive association
between variation in the Cys-C gene and abdomi-
nal aortic aneurysms growth [13,25,26]. One study
has concluded that moderate renal dysfunction
affects arteriosclerosis in any part of the body
[27]. Accordingly, we presumed that increased Cys-
C could possibly detect not only renal insufﬁciency,
but also stable plaque formation; thus arterioscle-
rosis in any part of the body including coronary
artery.
Study limitations
This study was conducted in patients without any
history of coronary artery disease. Cys-C was mea-
sured within 3 months before coronary angiography,
which was quite long term; the time differences
of measuring Cys-C might be pointed out. Further
studies should be necessary to clarify whether Cys-
C could be a marker for screening coronary artery
disease. Moreover, it should take the following mat-
ters into account to evaluate the patients with
Cys-C 0.90mg/l and those with Cys-C 0.89mg/l:
signiﬁcant differences in age and the number of
patients treated with -blocker or ACE-I/ARB. Some
studies have reported that ACE-I/ARB have no
signiﬁcant inﬂuence on the Cys-C level [28,29],
however, no study has proved the inﬂuence of
-blocker; it was uncertain whether -blocker
affected our study results.
Conclusion
In the patients without obvious renal dysfunction or
organic renal disease, Cys-C was useful to detect
renal insufﬁciency. In addition, Cys-C could possi-
bly predict coronary arteriosclerosis as well as HDL
cholesterol. The results of this study suggested that
Cys-C was useful for screening and detecting coro-
nary artery disease. Cys-C might also indicate the
severity of coronary arteriosclerosis.References
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